Categories: All CategoriesCorporateProductsPipelineFinancial Feb 12, 2021New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate CancerPipelineJan 08, 2021Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®ProductsDec 11, 2020New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene MutationsPipelineNov 16, 2020Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and ChinaPipelineNov 11, 2020New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid ArthritisPipelineOct 16, 2020German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic TestPipelineAug 21, 2020American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian CancerPipelineAug 10, 2020New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic ConditionsPipelineJul 31, 2020Medicare Expands Coverage for BRACAnalysis® CDx in Prostate CancerPipelineJul 29, 2020Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS TestPipelineJul 28, 2020Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®PipelineJul 07, 2020Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk PredictionProductsJul 01, 2020Myriad Launches New GeneSight® Psychotropic Patient Collection KitProductsJun 25, 2020New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological AssessmentPipelineJun 15, 2020Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National ProviderProducts Next page
